On June 26, Pfizer Inc. (NYSE:PFE) declared that the Phase 3 BASIS research results showed that its medication HYMPAVZI (marstacimab) was superior to other inhibitors in treating hemophilia A or B ...

Hympavzi has been given a list price of $795,600 per year before discounts and rebates, which Pfizer said was in line with other prophylactic treatments for haemophilia A or B currently available ...

Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions, after a weekly, subcutaneous shot from Pfizer was cleared for NHS use. The ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease immunoglobulin A nephropathy (IgAN).

Pfizer's HYMPAVZI Shows Superiority in Hemophilia A/B with Inhibitors in Phase 3 Study Pfizer Inc. (NYSE:PFE) is one of the undervalued S&P 500 stocks to buy according to hedge funds.

Pfizer: We Think Competitive Advantages Still Exist, but Signs of Erosion Weigh on Our Valuation Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion.